

One Embarcadero Center
Suite 2700
San Francisco, CA 94111-3776
PHONE (415) 591-5400
FAX (415) 591-5401
E-MAIL burrill@b-c.com
WEB www.burrillandco.com

FOR IMMEDIATE RELEASE

Biotech posts small gain in May

SAN FRANCISCO – June 1, 2011 – It was a quiet month for biotech with the Burrill Biotech Select Index recording a small 2.8 percent gain in May. However, it was a different story on the capital markets...although they finished strongly, with four straight days of gains bracketing the Memorial Day holiday, the Dow Jones Industrial Average ended the month in negative territory, closing down 1.9 percent. The NASDAQ Composite Index mirrored the performance of the Dow, dropping 1.3 percent. “It was an up and down month for the general markets,” said G. Steven Burrill, CEO, Burrill & Company, “investors have been spooked by high gas prices and the debt crisis in Europe.”

A leading gainer in the Select Index group was Affymetrix registering a 12.8 percent hike in its share price. The company announced that the U.S. Food and Drug Administration had cleared the addition of new gene expression reagents as accessories to its GeneChip® Microarray Instrument System for in vitro diagnostic use, which the company claims makes them the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Shares of Onyx jumped 13 percent despite the fact that the company reported a net loss of \$14.2 million for the first quarter 2011 compared to a net loss of \$1.5 million for the same period in 2010. The loss was greater than expected but investors warmed to the company’s strong product pipeline that contains several candidate drugs in the latter stages of clinical testing.

Gilead Sciences saw its shares climb 7.5 percent. The company reported that it had extended its funding support of the Gilead Sciences Research Centre at the Institute of Organic Chemistry and Biochemistry (IOCB) of the Academy of Sciences of the Czech Republic for an additional five years. Gilead says that it will provide a \$1.15 million annual donation to IOCB in order to continue to fund the Research Centre’s operations and ongoing research efforts.

On the regulatory front The U.S. Food and Drug Administration approved San Diego-based Optimer Pharmaceuticals’ Dificid (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD). The company’s shares closed the month up 15 percent.

Quiet month for IPOs

Only one US biotech company priced an IPO this month:

South San Francisco-based Solazyme, which transforms plant-based sugars into petroleum-based chemicals and fuels, raised \$198 million by offering 10.975 million shares at \$18, above the range of \$15 to \$17. The company had originally planned to offer 9.975 million shares, with the upside coming from additional primary shares; in total, the company raised 24 percent more than originally planned.

Solazyme, Inc. is a renewable oil and bioproducts company that transforms a range of low-cost plant-based sugars into high-value oils. Headquartered in South San Francisco, Solazyme's renewable products can replace or enhance oils derived from the world's three existing sources – petroleum, plants and animal fats. Initially, Solazyme is focused on commercializing its products into three target markets: fuels and chemicals, nutrition, and skin and personal care.

“Solazyme’s successful IPO will be encouraging news for other bioenergy companies that are currently waiting on the IPO runway, such as KiOR and Ceres,” noted Burrill. “Post-market performance of the newly minted biotech IPOs is also improving with the collective performance of the ten companies that have debuted in 2011 averaging 37 percent to date.”

Performance of Biotech IPOs completed in 2011:

Company	TICKER	IPO Price	Amount Raised (\$M)	Price 5/31/11	% Change
AcelRx	ACRX	\$5.00	40	\$4.80	-4.00
Fluidigm	FLDM	\$13.50	75	\$14.97	10.89
Gevo*	GEVO	\$15.00	107	\$19.28	28.53
BG Medicine	BGMD	\$7.00	35	\$7.25	3.57
Epocrates	EPOC	\$16.00	86	\$21.05	31.56
Endocyte*	ECYT	\$6.00	75	\$11.90	98.33
Pacira Pharmaceuticals	PCRX	\$7.00	42	\$14.30	104.29
Sagent Pharmaceuticals	SGNT	\$16.00	106	\$25.00	56.25
Tranzyme Pharma	TZYM	\$4.00	54	\$4.73	18.25
Solazyme	SZYM	\$18.00	198	22.53	25.17

*Burrill & Company is an investor in the company

Industry market cap

The industry closed the month with a collective market cap of \$412.92 billion (up 0.9 percent for the month and 10.8 percent year-to-date).

Burrill Biotech Indices

INDEX	12/31/2010	4/29/2011	5/31/2011	% CHANGE (MONTH)	% CHANGE (YTR)
Burrill Select	365.12	417.68	429.43	2.81%	17.61%
Burrill Large Cap	526.55	595.17	598.51	0.56%	13.67%
Burrill Mid- Cap	218.1	277.38	281.91	1.63%	29.26%
Burrill Small Cap	94.97	109.22	108.01	-1.11%	13.73%
Burrill Diagnostics	158.05	189.08	192.64	1.88%	21.89%
Personalized Medicine	106.26	116.2	120.65	3.83%	13.54%
Canadian Biotech	55.68	70.11	70.68	0.81%	26.94%
NASDAQ	2652.87	2873.54	2835.3	-1.33%	6.88%
DJIA	11577.51	12810.54	12569.79	-1.88%	8.57%
Amex Biotech	1297.61	1462.1	1481.36	1.32%	14.16%
Amex Pharma	305.88	329.75	340.26	3.19%	11.24%

About Burrill & Company

Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With more than \$1 billion in assets under management, the firm's businesses include venture capital, private equity, merchant banking and media. By leveraging the scientific and business networks of its investment team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe and Asia. For more information visit: www.burrillandco.com.

Upcoming Burrill & Company Events

The 2nd Annual Burrill Pan-Asia Life Sciences Meeting

June 26, 2011, The Grosvenor Auditorium at National Geographic Museum
Washington D.C.

http://www.burrillandco.com/pan_asia_2011/

The Burrill Personalized Medicine Meeting

October 03, 2011 - October 04, 2011

The San Francisco Airport Marriott
Burlingame, CA

http://www.burrillandco.com/personalized_medicine_2011/